The letter, signed through 207 doctors, 177 academics and 111 public fitness professionals, calls on the government to remove legal and technical barriers to expand the production of vaccines, diagnostic tests, remedies and other COVID-19 equipment.
We argue that Australia, and other rich countries, can do more to end the pandemic and do more.
The desire for urgent action
The COVID-19 pandemic is intensifying dramatically in emerging countries that, in addition to the spiral of infections in India, are expanding internationally in countries such as Argentina, Uruguay, Sweden, France, Turkey, Mongolia and Costa Rica.
Vaccine deployment wants to increase rapidly and uncontrolled transmission will inevitably lead to new variants that are possibly more infectious and resistant to vaccines.
To date, more than 1,060 million doses of vaccine have been administered worldwide, however, 37% of these doses were administered in the world’s 27 richest countries, representing 10. 5% of the world’s population.
Meanwhile, countries that make up 11% of the less wealthy have so far won only 1. 6% of vaccine doses, at this rate, most of the world’s population will remain unprotected until at least 2023.
Vaccine monopolization
Two of the world’s main barriers to immunization are the monopolization of vaccines and the means to produce them. The global one relies on the pharmaceutical industry and market forces to solve insufficient source and unfair distribution disorders, and that would possibly not work.
Rich countries have monopolized the global source of vaccines by purchasing advance bulk doses. By November 2020, 7. 5 billion doses had been booked, some of which were reserved through countries representing only 14% of the world’s population.
Rich countries have also invested little in COVAX, the global fair vaccine distribution programme. COVAX wants another $3. 2 billion just to succeed in its purpose of vaccinating 20% of the country’s population.
In addition, countries facing giant outbreaks have tightened export restrictions on their own vaccine supplies, excluding others.
This includes the European Union’s refusal to 3. 1 million doses in Australia this year. India also limited vaccine exports, delaying the delivery of 90 million doses to low-income countries.
The United States has also accumulated supplies, Biden’s management announced this week that it would now allow the export of raw tissues needed to make vaccines in India.
Monopolies on vaccine production
While vaccine hoarding is a concern, monopolies on the rights to produce vaccines are an even bigger problem.
Exclusive production rights for COVID-19 vaccines are maintained lately through a small number of companies. These high-level goods rights are enshrined in the World Trade Organization Agreement on Aspects of The Rights of High-Level Goods Trading, also known as TRIPS.
Under the TRIPS Agreement, WTO members must authorize patents of at least 20 years for new pharmaceuticals as well as other types of high-level asset protection.
TRIPS countries to invoke the compulsory pharmaceutical license, which patented inventions to be produced without the consent of the patent owner in an emergency.
But compulsory licensing can only be implemented product-to-product, and applies only to patents, to other types of wisdom and knowledge needed to make vaccines.
Countries also have a tendency to address diplomatic and industry tensions so as not to adopt such licenses. As far as we know, no country has issued a compulsory license for a COVID-19 vaccine.
The pandemic is also very bad in Latin America. “Almost a million lives have been lost in Latin America here. womb. . . the pandemic is accelerating in countries such as Argentina, Bolivia, Peru, Venezuela and Uruguay” https:// t . co / yl7HoWrrvH
Dependence on pharmaceutical forces and the market
So far, the world has the pharmaceutical industry and market forces to solve the problem, hoping that vaccine brands will voluntarily participate in licensing agreements with other brands to increase supply.
But voluntary licences have been used little to date, when used it was done ad hoc and opaque, under restrictive conditions.
AstraZeneca, Gamaleya / Sputnik V and Sinopharm are the only corporations that have implemented voluntary licenses for COVID-19 vaccines. AstraZeneca, for example, has legal SK Bio in South Korea, the Serum Institute of India and CSL in Australia to manufacture the vaccine. .
The reluctance of other corporations to participate in these agreements means that production capacity in Asia, Africa and Latin America is not being used.
The pharmaceutical industry is heavily invested in the prestige quo. Pfizer and Moderna expect to generate $15 billion and $18. 4 billion in profits respectively in 2021, only on existing source agreements.
People’s Vaccine Alliance believes Pfizer, Johnson
What Australia has done so far
Australia has benefited to date, offering A$80 million to COVAX (especially for low-income countries).
It also pledged $523 million for the Regional Vaccine Access and Safety Initiative, which provides an aptitude formula for immunizations and $100 million for the Quad initiative across India, Japan, Australia and the United States, which aims to distribute one billion doses in the Indo-Pacific. Region until 2022.
Australia has also provided 8,840 doses of the AstraZeneca vaccine to PNG for frontline fitness staff and has negotiated with the EU 1 million of its own traditional doses for PNG. Canberra has also promised doses to Timor-Leste, the Solomon Islands and Vanuatu.
These contributions are vital steps to meet immediate needs, but they will not go far enough away from themselves.
Other measures Australia wants to take
Increasing vaccines globally will require governments to remove legal and technical barriers to their production.
To help remove legal barriers, the Australian government deserves a proposal across India and South Africa in October 2020 to waive intellectuals’ asset rights over COVID-19 medical products.
This proposal, known as the ‘TRIPS repeal’, is now supported by more than a hundred of the 164 WTO member states, but has been blocked or blocked through the United States, the EU, Japan, Canada and Australia.
Australia will have some other possibility when discussed at an TRIPS Council meeting later this week.
To remove technical barriers, Australia will have to use its influence to convince pharmaceutical corporations to share their wisdom and move their technologies to low- and middle-income countries.
Australia is also expected to approve the COVID-19 Generation Access Group (C-TAP), which was established last May through the World Health Organization and has not yet been used to date.
C-TAP is based on voluntary commitments from pharmaceutical companies. For this to work, governments will need to offer incentives or require pharmaceutical companies to provide a percentage of their high-level properties, knowledge and experience as a condition for public investment in studies and development.
More than 700 fitness professionals and academics see government leadership in these spaces as a component of our pandemic response.
Please specify the maximum appropriate category to facilitate the processing of your application.
Thank you for taking the time to send your feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.